TheraRadar

Briefs tagged "BMS"

2 briefs

AbbVie Amgen Arvinas BMS Biogen CNS CRISPR Therapeutics Eisai Eli Lilly FDA IBD IGF-1R J&J Merck Novartis Pfizer Regeneron Roche Sandoz Sanofi TL1A Takeda Vertex autoimmune biosimilars bispecific cardiovascular competitive landscape drug development gene therapy genetics immunotherapy metabolic oncology ophthalmology patent cliff protein degradation rare disease regulatory
15 min read

Thalidomide Accidentally Invented Targeted Protein Degradation

Nobody knew why it caused birth defects for 50 years. The answer launched a new era of drug design.

The worst drug disaster in pharmaceutical history accidentally revealed how to hijack the cell's protein disposal system. Celgene turned thalidomide derivatives into a $12.8B franchise without knowing the mechanism. When scientists finally identified the target in 2010, it launched targeted protein degradation - now one of the most promising modalities in drug development, with its first FDA-approved drug.

Read the full brief
drug developmentoncologyprotein degradationArvinasPfizer
11 min read

KRAS: 40 Years Undruggable, Then Drugged. Then What?

It took 40 years to drug KRAS. The real competition started the day it worked.

KRAS mutations drive roughly 30% of all cancers. For four decades, no one could drug it. In 2021, sotorasib cracked the target. Now three approaches - next-gen G12C, G12D inhibitors, and pan-KRAS degraders - are racing to turn a proven mechanism into a blockbuster.

Read the full brief
oncologydrug developmentcompetitive landscapeAmgenRoche

Get the next Brief in your inbox — free

Every drug has multiple stories. Most never get told. One brief every week. No spam.

Archive lives at /briefs/. Unsubscribe anytime.